Trevi Therapeutics, Inc.

TRVI

$17.06

+0.06%

2026-09-03 16:00:00 EDT+$0.01

Healthcare

Biotechnology

NASDAQ

Active Trading

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically ...

Historical Employee Count of TRVI

Current

Change

+30.77%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	34	10-K	Mar 17, 2026	View
Dec 31, 2024	26	10-K	Mar 18, 2025	View
Dec 31, 2023	25	10-K	Mar 20, 2024	View
Dec 31, 2022	25	10-K	Mar 16, 2023	View
Dec 31, 2021	24	10-K	Mar 17, 2022	View

Supply Chain of TRVI

Upstream / Downstream / Proxies

Upstream

Keenova Therapeutics plc (f/k/a Mallinckrodt plc, merged with Endo)OTC:MNKTQUndisclosed Contract Manufacturing Organization (CMO)Undisclosed Clinical Research Organization (CRO)Vitalograph LtdRutgers, The State University of New JerseyMentiNova LLCKeenova Therapeutics plc (as IP Licensor, via Endo/Penwest legacy)OTC:MNKTQ

Downstream

No Commercial Customers (Pre-Revenue)

Proxies

Cara Therapeutics, Inc.NASDAQ:CARA Aquestive Therapeutics, Inc.NASDAQ:AQST OptiNose, Inc.NASDAQ:OPTN

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer